Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 16, 2006. The report details a specific corporate action regarding the repurchase of the company's own shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 675,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,464.08 pence per share.
- Treasury Shares Held: 143,454,678 shares (post-purchase).
- Shares in Issue: 5,824,079,261 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on February 16, 2006, authorized by shareholders at the Annual General Meeting on May 25, 2005. The filing text does not provide comparative data to prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 675,000 shares purchased at 1,464.08 pence per share.
- Confirm the remaining authorization limit for share buybacks under the May 25, 2005 shareholder resolution.
- Review the company's latest Form 20-F for comprehensive financial performance data not included in this 6-K.